Repligen Corporation (RGEN)
Debt-to-capital ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | 
| Total stockholders’ equity | US$ in thousands | 1,972,720 | 1,971,200 | 397,272 | 1,750,070 | 65,769 | 
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 
December 31, 2024 calculation
            Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
            = $—K ÷ ($—K + $1,972,720K)
            = 0.00        
The debt-to-capital ratio for Repligen Corporation has consistently remained at 0.00 from December 31, 2020, to December 31, 2024. This indicates that the company has not used any debt financing as part of its capital structure during this period. A debt-to-capital ratio of 0.00 signifies that the company's capital structure is predominantly equity-funded, which can be viewed positively as it implies lower financial risk and reliance on debt for operations and growth.
Peer comparison
Dec 31, 2024
Company name
                    Symbol
                    Debt-to-capital ratio
                Repligen Corporation
                            RGEN
                            0.00
                        ADMA Biologics Inc
                            ADMA
                            0.17
                        Amgen Inc
                            AMGN
                            0.00
                        Bio-Techne Corp
                            TECH
                            0.00
                        Biogen Inc
                            BIIB
                            0.21
                        Gilead Sciences Inc
                            GILD
                            0.00
                        Halozyme Therapeutics Inc
                            HALO
                            0.00
                        Krystal Biotech Inc
                            KRYS
                            0.00
                        Moderna Inc
                            MRNA
                            0.00
                        Neurocrine Biosciences Inc
                            NBIX
                            0.00
                        Vericel Corp Ord
                            VCEL
                            0.00